Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Hussein A TawbiDirk SchadendorfEvan J LipsonPaolo Antonio AsciertoLuis MatamalaErika Castillo GutiérrezPiotr RutkowskiHelen J GogasChristopher D LaoJuliana Janoski De MenezesStéphane DalleAna AranceJean-Jacques GrobShivani SrivastavaMena AbaskharounMelissa HamiltonSarah KeidelKaty L SimonsenAnne Marie SobieskBin LiF Stephen HodiGeorgina V Longnull nullPublished in: The New England journal of medicine (2022)
The inhibition of two immune checkpoints, LAG-3 and PD-1, provided a greater benefit with regard to progression-free survival than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma. Relatlimab and nivolumab in combination showed no new safety signals. (Funded by Bristol Myers Squibb; RELATIVITY-047 ClinicalTrials.gov number, NCT03470922.).